2026 Q1 -tulosraportti
Äänite tulossa
2 päivää sitten
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 187 | - | - | ||
| 18 228 | - | - | ||
| 3 320 | - | - | ||
| 21 700 | - | - | ||
| 2 565 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 13.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 10.4.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·8 t sittenChat GPT: Part 2 3. The NHS/RTP track is important This is very interesting: They are now trying to get funding indirectly via the NHS program: “Respiratory Transformation Pathway”. This means: * NHS can potentially finance the rollout, * which reduces sales friction, * and can make scaling much faster. The 10 million GBP program is explicitly mentioned. This seems like an attempt to get: * publicly funded national rollout, * instead of traditional heavy enterprise sales. It can be strategically smart. 4. They are building an AI angle The company mentions: * AI-driven features, * automation, * master data, * clinical decision support. This is important because: the market gives higher value to software companies that can connect: * health data, * workflow, * and AI. But for now, this seems more like positioning than large commercial revenues. 5. The grant portal is both a strength and a weakness This is still a stable foundation: * ~40 % market share in Norway, * recurring subscription revenues, * public sector customers. But: municipalities are cutting costs. They say directly that: * customer churn increased, * municipalities are cutting "non-obligatory" services. This is a real risk. At the same time, they show that: voluntary organizations found over 60 MNOK in support via the solution. That strengthens the product's value proposition. 6. Sweden seems weaker than the market perhaps hoped They write quite clearly between the lines: * the market is more difficult, * more fragmented, * and go-to-market must be evaluated. It is not negatively catastrophic, but also not a sign of rapid scaling. 7. Intangible assets are high They have: * 50,2 MNOK in intangible assets, * against 16,7 MNOK in revenue. This is high. Consists of: * developed platforms, * goodwill from the OSINT acquisition. Risk: If growth fails to materialize, the market may start to question these values. My assessment of the message Fundamentally: This is clearly better than previous annual reports. It looks like: * financial cleanup work has actually worked, * and that the company now has a bit more breathing room. What the market probably focuses most on Positive 1. EBITDA significantly improved 2. Debt dramatically reduced 3. Positive cash flow 4. AstraZeneca/NHS dialogue continues 5. 60–70 MNOK ARR potential explicitly mentioned Negative 1. No signed UK agreement yet 2. Falling revenues 3. Customer churn in the municipal market 4. Still a loss on the bottom line Overall investment case now Induct now seems more like: * a restructured software/healthtech case, than a company in acute financial distress. The future value is probably almost entirely determined by: * whether the UK/AstraZeneca/NHS track materializes, * and whether they manage to convert pilot/project to scalable ARR. If they succeed: today's size can be very small relative to the potential. If they fail: they are left with: * a moderate Norwegian software business, * weak growth, * and limited scaling.- ·8 t sittenChat GPT: Part 1 This is a quite interesting annual report from Induct. It shows a company that is still high-risk, but where much of the financial crisis seems to have been cleaned up — while the case now largely revolves around whether they succeed commercially in the UK through AstraZeneca/NHS. Briefly summarized Positive * Strong improvement in operations and balance sheet. * EBITDA improved from 0.6 MNOK to 7.5 MNOK. * Debt significantly reduced. * Equity ratio up to 73.9 %. * Positive operational cash flow. * AstraZeneca dialogue described as "positive". * UK case can potentially yield 60–70 MNOK ARR upon full rollout. * Induct has an extremely strong position in the Norwegian health sector (95 %+ of health enterprises). Negative / risk * Still a bottom-line deficit (-7.1 MNOK). * Revenues are falling. * Customer churn in Tilskuddsportalen. * Swedish expansion is slower than hoped. * The UK agreement is still not signed. * The company is still dependent on growth in healthcare to succeed. * Intangible assets are very high relative to revenues. The most important in the report 1. The company has completed a real financial turnaround This is perhaps the most important point. They have: * significantly reduced costs, * refinanced, * converted debt to shares, * improved liquidity, * and gone from almost financial stress to a much stronger balance sheet. Figures: * EBITDA: 7.5 MNOK (up from 0.6) * Liquidity: 2.7 MNOK (up from 0.4) * Equity ratio: 73.9 % (up from 43.2 %) * Long-term debt reduced by 76 % This means: The market no longer primarily needs to fear bankruptcy/issuance pressure in the same way as before. 2. The entire case is now about UK + AstraZeneca This is clearly the biggest trigger. They say directly: * the dialogue with AstraZeneca has developed positively, * both parties want a national rollout, * a subscription model is being considered, * and the ARR potential upon full rollout is 60–70 MNOK. That is enormous relative to today's revenue of only 16.7 MNOK. If this succeeds: * the company can potentially multiply revenues several times, * get higher software multiples, * and become a much more attractive SaaS case. But: The agreement is still not signed. It is therefore still a "show me" case.
·1 päivä sittenReplenishment, or rapidly heading towards an ATL price in the stock, that is the question. I think the latter is highly relevant.·11 t sittenA statement from the company is coming soon. They must step up and clarify some things.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Äänite tulossa
2 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8 t sittenChat GPT: Part 2 3. The NHS/RTP track is important This is very interesting: They are now trying to get funding indirectly via the NHS program: “Respiratory Transformation Pathway”. This means: * NHS can potentially finance the rollout, * which reduces sales friction, * and can make scaling much faster. The 10 million GBP program is explicitly mentioned. This seems like an attempt to get: * publicly funded national rollout, * instead of traditional heavy enterprise sales. It can be strategically smart. 4. They are building an AI angle The company mentions: * AI-driven features, * automation, * master data, * clinical decision support. This is important because: the market gives higher value to software companies that can connect: * health data, * workflow, * and AI. But for now, this seems more like positioning than large commercial revenues. 5. The grant portal is both a strength and a weakness This is still a stable foundation: * ~40 % market share in Norway, * recurring subscription revenues, * public sector customers. But: municipalities are cutting costs. They say directly that: * customer churn increased, * municipalities are cutting "non-obligatory" services. This is a real risk. At the same time, they show that: voluntary organizations found over 60 MNOK in support via the solution. That strengthens the product's value proposition. 6. Sweden seems weaker than the market perhaps hoped They write quite clearly between the lines: * the market is more difficult, * more fragmented, * and go-to-market must be evaluated. It is not negatively catastrophic, but also not a sign of rapid scaling. 7. Intangible assets are high They have: * 50,2 MNOK in intangible assets, * against 16,7 MNOK in revenue. This is high. Consists of: * developed platforms, * goodwill from the OSINT acquisition. Risk: If growth fails to materialize, the market may start to question these values. My assessment of the message Fundamentally: This is clearly better than previous annual reports. It looks like: * financial cleanup work has actually worked, * and that the company now has a bit more breathing room. What the market probably focuses most on Positive 1. EBITDA significantly improved 2. Debt dramatically reduced 3. Positive cash flow 4. AstraZeneca/NHS dialogue continues 5. 60–70 MNOK ARR potential explicitly mentioned Negative 1. No signed UK agreement yet 2. Falling revenues 3. Customer churn in the municipal market 4. Still a loss on the bottom line Overall investment case now Induct now seems more like: * a restructured software/healthtech case, than a company in acute financial distress. The future value is probably almost entirely determined by: * whether the UK/AstraZeneca/NHS track materializes, * and whether they manage to convert pilot/project to scalable ARR. If they succeed: today's size can be very small relative to the potential. If they fail: they are left with: * a moderate Norwegian software business, * weak growth, * and limited scaling.
- ·8 t sittenChat GPT: Part 1 This is a quite interesting annual report from Induct. It shows a company that is still high-risk, but where much of the financial crisis seems to have been cleaned up — while the case now largely revolves around whether they succeed commercially in the UK through AstraZeneca/NHS. Briefly summarized Positive * Strong improvement in operations and balance sheet. * EBITDA improved from 0.6 MNOK to 7.5 MNOK. * Debt significantly reduced. * Equity ratio up to 73.9 %. * Positive operational cash flow. * AstraZeneca dialogue described as "positive". * UK case can potentially yield 60–70 MNOK ARR upon full rollout. * Induct has an extremely strong position in the Norwegian health sector (95 %+ of health enterprises). Negative / risk * Still a bottom-line deficit (-7.1 MNOK). * Revenues are falling. * Customer churn in Tilskuddsportalen. * Swedish expansion is slower than hoped. * The UK agreement is still not signed. * The company is still dependent on growth in healthcare to succeed. * Intangible assets are very high relative to revenues. The most important in the report 1. The company has completed a real financial turnaround This is perhaps the most important point. They have: * significantly reduced costs, * refinanced, * converted debt to shares, * improved liquidity, * and gone from almost financial stress to a much stronger balance sheet. Figures: * EBITDA: 7.5 MNOK (up from 0.6) * Liquidity: 2.7 MNOK (up from 0.4) * Equity ratio: 73.9 % (up from 43.2 %) * Long-term debt reduced by 76 % This means: The market no longer primarily needs to fear bankruptcy/issuance pressure in the same way as before. 2. The entire case is now about UK + AstraZeneca This is clearly the biggest trigger. They say directly: * the dialogue with AstraZeneca has developed positively, * both parties want a national rollout, * a subscription model is being considered, * and the ARR potential upon full rollout is 60–70 MNOK. That is enormous relative to today's revenue of only 16.7 MNOK. If this succeeds: * the company can potentially multiply revenues several times, * get higher software multiples, * and become a much more attractive SaaS case. But: The agreement is still not signed. It is therefore still a "show me" case.
- ·1 päivä sittenReplenishment, or rapidly heading towards an ATL price in the stock, that is the question. I think the latter is highly relevant.·11 t sittenA statement from the company is coming soon. They must step up and clarify some things.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 187 | - | - | ||
| 18 228 | - | - | ||
| 3 320 | - | - | ||
| 21 700 | - | - | ||
| 2 565 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 13.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 10.4.2025 |
2026 Q1 -tulosraportti
Äänite tulossa
2 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 13.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 13.5. | ||
2025 Q4 -tulosraportti 12.2. | ||
2025 Q3 -tulosraportti 13.11.2025 | ||
2025 Q2 -tulosraportti 14.8.2025 | ||
2025 Q1 -tulosraportti 10.4.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·8 t sittenChat GPT: Part 2 3. The NHS/RTP track is important This is very interesting: They are now trying to get funding indirectly via the NHS program: “Respiratory Transformation Pathway”. This means: * NHS can potentially finance the rollout, * which reduces sales friction, * and can make scaling much faster. The 10 million GBP program is explicitly mentioned. This seems like an attempt to get: * publicly funded national rollout, * instead of traditional heavy enterprise sales. It can be strategically smart. 4. They are building an AI angle The company mentions: * AI-driven features, * automation, * master data, * clinical decision support. This is important because: the market gives higher value to software companies that can connect: * health data, * workflow, * and AI. But for now, this seems more like positioning than large commercial revenues. 5. The grant portal is both a strength and a weakness This is still a stable foundation: * ~40 % market share in Norway, * recurring subscription revenues, * public sector customers. But: municipalities are cutting costs. They say directly that: * customer churn increased, * municipalities are cutting "non-obligatory" services. This is a real risk. At the same time, they show that: voluntary organizations found over 60 MNOK in support via the solution. That strengthens the product's value proposition. 6. Sweden seems weaker than the market perhaps hoped They write quite clearly between the lines: * the market is more difficult, * more fragmented, * and go-to-market must be evaluated. It is not negatively catastrophic, but also not a sign of rapid scaling. 7. Intangible assets are high They have: * 50,2 MNOK in intangible assets, * against 16,7 MNOK in revenue. This is high. Consists of: * developed platforms, * goodwill from the OSINT acquisition. Risk: If growth fails to materialize, the market may start to question these values. My assessment of the message Fundamentally: This is clearly better than previous annual reports. It looks like: * financial cleanup work has actually worked, * and that the company now has a bit more breathing room. What the market probably focuses most on Positive 1. EBITDA significantly improved 2. Debt dramatically reduced 3. Positive cash flow 4. AstraZeneca/NHS dialogue continues 5. 60–70 MNOK ARR potential explicitly mentioned Negative 1. No signed UK agreement yet 2. Falling revenues 3. Customer churn in the municipal market 4. Still a loss on the bottom line Overall investment case now Induct now seems more like: * a restructured software/healthtech case, than a company in acute financial distress. The future value is probably almost entirely determined by: * whether the UK/AstraZeneca/NHS track materializes, * and whether they manage to convert pilot/project to scalable ARR. If they succeed: today's size can be very small relative to the potential. If they fail: they are left with: * a moderate Norwegian software business, * weak growth, * and limited scaling.
- ·8 t sittenChat GPT: Part 1 This is a quite interesting annual report from Induct. It shows a company that is still high-risk, but where much of the financial crisis seems to have been cleaned up — while the case now largely revolves around whether they succeed commercially in the UK through AstraZeneca/NHS. Briefly summarized Positive * Strong improvement in operations and balance sheet. * EBITDA improved from 0.6 MNOK to 7.5 MNOK. * Debt significantly reduced. * Equity ratio up to 73.9 %. * Positive operational cash flow. * AstraZeneca dialogue described as "positive". * UK case can potentially yield 60–70 MNOK ARR upon full rollout. * Induct has an extremely strong position in the Norwegian health sector (95 %+ of health enterprises). Negative / risk * Still a bottom-line deficit (-7.1 MNOK). * Revenues are falling. * Customer churn in Tilskuddsportalen. * Swedish expansion is slower than hoped. * The UK agreement is still not signed. * The company is still dependent on growth in healthcare to succeed. * Intangible assets are very high relative to revenues. The most important in the report 1. The company has completed a real financial turnaround This is perhaps the most important point. They have: * significantly reduced costs, * refinanced, * converted debt to shares, * improved liquidity, * and gone from almost financial stress to a much stronger balance sheet. Figures: * EBITDA: 7.5 MNOK (up from 0.6) * Liquidity: 2.7 MNOK (up from 0.4) * Equity ratio: 73.9 % (up from 43.2 %) * Long-term debt reduced by 76 % This means: The market no longer primarily needs to fear bankruptcy/issuance pressure in the same way as before. 2. The entire case is now about UK + AstraZeneca This is clearly the biggest trigger. They say directly: * the dialogue with AstraZeneca has developed positively, * both parties want a national rollout, * a subscription model is being considered, * and the ARR potential upon full rollout is 60–70 MNOK. That is enormous relative to today's revenue of only 16.7 MNOK. If this succeeds: * the company can potentially multiply revenues several times, * get higher software multiples, * and become a much more attractive SaaS case. But: The agreement is still not signed. It is therefore still a "show me" case.
- ·1 päivä sittenReplenishment, or rapidly heading towards an ATL price in the stock, that is the question. I think the latter is highly relevant.·11 t sittenA statement from the company is coming soon. They must step up and clarify some things.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Euronext Growth Oslo
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 4 187 | - | - | ||
| 18 228 | - | - | ||
| 3 320 | - | - | ||
| 21 700 | - | - | ||
| 2 565 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt